glucocorticoid

Overview

Glucocorticoids are a class of steroid hormones and widely used anti-inflammatory and immunosuppressive agents that act primarily through the glucocorticoid receptor. Endogenously, they are central regulators of metabolism, stress responses, and immune homeostasis; pharmacologically, they are among the most important therapies for inflammatory, autoimmune, allergic, and transplant-related conditions. Their effects are pleiotropic: they can suppress proinflammatory cytokine production, alter leukocyte trafficking and activation, and influence tissue repair and metabolic pathways.

In biomedical research, glucocorticoids are studied both as therapeutic agents and as biologically active signals within disease microenvironments. Recent work has highlighted their role in rheumatoid arthritis, Sjögren’s disease, inflammatory bowel and kidney disorders, cancer immunotherapy toxicity, and T-cell differentiation. At the same time, studies continue to examine glucocorticoid-related adverse effects, including infection risk, cardiovascular associations, and steroid resistance, as well as mechanisms of local glucocorticoid metabolism and receptor signaling.

Recent Publications Summary

Recent publications on glucocorticoid focused largely on its role as a treatment component or exposure variable in autoimmune and inflammatory disease, with several studies examining dose, combination therapy, and downstream biologic effects. In systemic lupus erythematosus, longitudinal modeling from the LUMINA cohort identified highest-ever daily glucocorticoid dose as the strongest predictor of future organic neuropsychiatric damage, ahead of social support deficits and retirement status 42486615Jul. In giant cell arteritis, a nationwide French database study found that although high-dose glucocorticoid trajectories declined over time, cumulative exposure remained substantial, with a mean 2-year dose of 7.6 g among patients diagnosed in 2022; the study also evaluated associations between cumulative exposure and mortality, serious infections, major adverse cardiovascular events, and osteoporotic fractures 42414038Jul.

Other real-world studies examined glucocorticoid use in routine care and its relationship to outcomes. In rheumatoid arthritis, 75% of newly diagnosed patients received glucocorticoids during the first year of treatment, most often started at the first visit, with a mean prescribed dose of 9.3 mg/day and frequent use of both oral tablets and intra-articular injections; the study also assessed one-year dose-dependent infection risk 42283855Jun. In ANCA-associated vasculitis, a longitudinal cohort study reported no benefit from adding low-dose glucocorticoids to maintenance treatment for reducing major relapses, hospitalization, or damage accumulation 42342286Jun. In IgA nephropathy, telitacicept plus glucocorticoids produced a greater reduction in 24-hour proteinuria at 6 months than telitacicept alone, while glomerular filtration rate increased slightly in both groups without a significant between-group difference 41964393Apr.

Mechanistic and translational studies also highlighted glucocorticoid signaling in immune regulation. A cell-intrinsic glucocorticoid biosynthesis and sensing circuit was shown to maintain a homeostatic Th17 cell state, with CYP11A1-dependent glucocorticoid production and glucocorticoid receptor signaling distinguishing homeostatic from pro-inflammatory Th17 cells; the authors proposed implications for treating Th17-mediated autoimmunity 42285103Jun. In severe cerebral venous thrombosis, a mechanistic exploratory study investigated how glucocorticoids combined with anticoagulation may modulate central NLRP3/NETosis-driven inflammation 42050165Apr. In asthma, Epimedium brevicornum Maxim and Ligustrum lucidum Ait were reported to enhance glucocorticoid-associated anti-inflammatory effects through the cAMP/PKA/CREB pathway 41690429Feb.

Additional reports described glucocorticoid use in chronic graft-versus-host disease and a renal case report. In heavily pretreated chronic GVHD, belumosudil treatment was associated with glucocorticoid dose reduction as one of the assessed outcomes in a multicenter real-world cohort 42198791May. In recurrent IgA1-λ-type proliferative glomerulonephritis with monoclonal immunoglobulin deposits, complete remission was initially achieved with glucocorticoid monotherapy, and remission after relapse was later achieved with cyclophosphamide followed by mycophenolate mofetil 41192914Nov.

What Changes, What Holds

1. Higher glucocorticoid exposure appears to drive later organ damage and remains a major cumulative burden in giant cell arteritis
REINFORCES The new lupus and giant cell arteritis data sharpen the baseline warning that glucocorticoids carry important adverse effects and dose-related harms. They do not alter the core account of glucocorticoids as anti-inflammatory therapy, but they strengthen the case that exposure intensity matters clinically, especially for neuropsychiatric damage and long-term toxicity. The giant cell arteritis findings also suggest that reducing high-dose trajectories has not eliminated substantial cumulative exposure. 42486615Jul42414038Jul

2. Routine glucocorticoid use remains common in inflammatory disease, but low-dose maintenance benefit is uncertain
REINFORCES These studies mostly confirm glucocorticoids as a frequent component of real-world autoimmune care while adding a cautionary note about limited incremental benefit in some settings. The rheumatoid arthritis and IgA nephropathy reports fit the established therapeutic role, whereas the vasculitis cohort weakens any assumption that low-dose glucocorticoids reliably improve maintenance outcomes. Together they support the baseline view of glucocorticoids as useful but context-dependent, with benefit and risk varying by disease and regimen. 42283855Jun42342286Jun41964393Apr

3. Glucocorticoid signaling can be generated locally to sustain a homeostatic Th17 state
NEW DIRECTION The Th17 work adds a previously unmentioned role to the baseline, which already covers immune regulation but not cell-intrinsic glucocorticoid production. It suggests that glucocorticoids are not only systemic hormones or drugs but can be synthesized and sensed within an immune-cell circuit that helps distinguish homeostatic from inflammatory Th17 cells. That is a mechanistic extension rather than a contradiction, and it may matter for how Th17-mediated autoimmunity is targeted. 42285103Jun

4. Glucocorticoids may be used as a dose-sparing adjunct in chronic graft-versus-host disease and can induce remission in a renal case report
REINFORCES These reports stay within the established therapeutic frame: glucocorticoids remain a treatment tool, sometimes as monotherapy and sometimes as part of combination care. The graft-versus-host disease cohort mainly adds real-world evidence that steroid burden can be reduced during other therapy, while the glomerulonephritis case illustrates another disease-specific use. Neither finding challenges the baseline; both simply extend its clinical breadth. 42198791May41192914Nov

Overview update candidates: cell-intrinsic glucocorticoid biosynthesis and sensing in Th17 cells as a new mechanistic role.